The role of the endogenous opioid system in polycystic ovary syndrome

Slides:



Advertisements
Similar presentations
Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome  Madelon van Wely, Ph.D.,
Advertisements

Proopiomelanocortin (POMC) processing
Adipose tissue insulin resistance in peripubertal girls with first-degree family history of polycystic ovary syndrome  Andréanne Trottier, B.Sc., Marie-Claude.
Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M
Association of abdominal obesity, insulin resistance, and oxidative stress in adipose tissue in women with polycystic ovary syndrome  Li Chen, M.S., Wen.
Alison Berent-Spillson, Ph. D. , Tiffany Love, Ph. D
Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries  Robert L. Rosenfield, M.D., Kristen Wroblewski,
The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study  Jeff G. Wang, M.D., Richard A. Anderson,
The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report  Ricardo Azziz, M.D., M.P.H., Enrico Carmina,
Male contraception Fertility and Sterility
Adipose tissue and reproduction in women
The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition  Lorraine Dennerstein,
Comparison of hormonal and metabolic markers after a high-fat, Western meal versus a low-fat, high-fiber meal in women with polycystic ovary syndrome 
Kalliopi Kotsa, M. D. , Ph. D. , Maria P. Yavropoulou, M. D
Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters  Enrico Carmina, M.D., Francesco.
Michal Youngster, M. D. , Valerie L. Ward, M. D. , M. P. H. , Emily A
Dennis J. Hand, Ph. D. , Vanessa L. Short, Ph. D. , M. P. H. , Diane J
The spectrum of androgen excess disorders
Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome 
Neohormones as biomarkers of reproductive health
Insulin resistance in oligomenorrheic infertile women with non-polycystic ovary syndrome  Shirei Ohgi, M.D., Koji Nakagawa, M.D., Ph.D., Rieko Kojima,
Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study  Angela Kerchner, B.A., Whitney Lester,
Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels 
Shahin Ghadir, M.D., Ricardo Azziz, M.D., M.P.H., M.B.A. 
Expression of growth differentiation factor-9 and bone morphogenetic protein-15 in oocytes and cumulus granulosa cells of patients with polycystic ovary.
Rebecca A. Feldman, M. D. , Kathleen O'Neill, M. D. , Samantha F
Efficacy of metformin therapy in adolescent girls with androgen excess: relation to sex hormone–binding globulin and androgen receptor polymorphisms 
Functional neuroimaging of emotional processing in women with polycystic ovary syndrome: a case-control pilot study  Courtney A. Marsh, M.D., M.P.H.,
Role of androgen-mediated enhancement of erythropoiesis in the increased body iron stores of patients with polycystic ovary syndrome  Héctor F. Escobar-Morreale,
Evolutionary determinants of polycystic ovary syndrome: part 1
Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic.
Ontogeny of the ovary in polycystic ovary syndrome
Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens 
Enhanced neuroactivation during verbal memory processing in postmenopausal women receiving short-term hormone therapy  Carol C. Persad, Ph.D., Jon-Kar.
Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis  Shiqin Zhu, M.D., Bingqian Zhang, M.D.,
Volume 128, Issue 5, Pages (March 2007)
Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular.
N-WASP Generates a Buzz at Membranes on the Move
Andrew C. Bjonnes, M.S., Richa Saxena, Ph.D., Corrine K. Welt, M.D. 
Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.
Hyperglycemia Stimulates Activation of Nuclear Factor κB (NFκB) in Mononuclear Cells (MNC) of Women With Polycystic Ovary Syndrome (PCOS)  F. Gonzalez,
Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity  Jean-Patrice Baillargeon, M.D.,
Introduction Fertility and Sterility
Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D. 
Increased secretion of amylin in women with polycystic ovary syndrome
Prevalence of polycystic ovary syndrome in adolescents
Tiffany Love, B. S. , Yolanda R. Smith, M. D. , M. S. , Carol C
Fleur R. Cattrall, M. B. B. S. , Beverley J. Vollenhoven, M. B. B. S
Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment  Richard Fleming, Ph.D.,
Banu Ucar, M. D. , Volkan Noyan, M. D. , Osman Caglayan, M. D
Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial  Antoni J. Duleba, M.D.,
Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin  Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.
Antecubital vein venous sampling does not distort circulating levels of peptide and sex steroid hormones  Michael P. Diamond, M.D., Michael Kruger, M.S.,
Manuel Maliqueo, Ph. D. , Bárbara Echiburú, Ph. D
Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men  Subodhsingh Chauhan, M.D.,
Dijana Hadžiomerović, M. D. , Bernhard Rabenbauer, M. D
Paolo Moghetti, M.D.  Fertility and Sterility 
Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome  Madelon van Wely, Ph.D.,
Insulin growth factors may be implicated in human sperm capacitation
Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions  Kristen Farrell, M.S.,
Inappropriate gonadotropin secretion in polycystic ovary syndrome
Tsan-Hon Liou, M. D. , Ph. D. , Jen-Hung Yang, M. D. , Ph. D
Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation  Reshef.
Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk?  Nadine M.P. Daan, M.D., Yvonne V.
Decrease in adiponectin levels in women with polycystic ovary syndrome after an oral glucose tolerance test  Dimitrios Panidis, M.D., Ph.D., Dimitrios.
Androgen responses to adrenocorticotropic hormone infusion among individual women with polycystic ovary syndrome  Kevin H. Maas, M.D., Ph.D., Sandy Chuan,
Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels 
Diabetes mellitus and insulin resistance in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis 
In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation 
Adipocytes from women with polycystic ovary syndrome demonstrate altered phosphorylation and activity of glycogen synthase kinase 3  Wendy Chang, M.D.,
Presentation transcript:

The role of the endogenous opioid system in polycystic ovary syndrome Aimee D. Eyvazzadeh, M.D., M.P.H., Kathryn P. Pennington, M.D., Rodica Pop-Busui, M.D., Ph.D., MaryFran Sowers, Ph.D., Jon-Kar Zubieta, M.D., Ph.D., Yolanda R. Smith, M.D., M.S.  Fertility and Sterility  Volume 92, Issue 1, Pages 1-12 (July 2009) DOI: 10.1016/j.fertnstert.2009.05.012 Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Centrally mediated and peripherally mediated effects of the opioid system. Fertility and Sterility 2009 92, 1-12DOI: (10.1016/j.fertnstert.2009.05.012) Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Hypothalamic production of β-endorphin. Pre-proopiomelanocortin (POMC) generates several peptides, including γ-MSH, adrenocorticotropic hormone (ACTH), which is cleaved to produce corticotropin-like intermediate lobe peptide (CLIP) and α-melanocyte-stimulating hormone (α-MSH), as well as β-lipotropin (β-LPH), which is cleaved to produce γ-LPH, β-MSH, and β-endorphin. Fertility and Sterility 2009 92, 1-12DOI: (10.1016/j.fertnstert.2009.05.012) Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions

Figure 3 Three-dimensional PET image of μ-opioid receptor distribution in the human brain. The μ-opioid receptor availability was quantified with positron emission tomography and the μ-opioid receptor selective radiotracer [11C] carfentanil. High receptor concentrations are shown in limbic and paralimbic “cognitive–emotional” associative regions, such as the cingulate and frontal cortex, as well as in the insular cortex, basal ganglia, amygdala, thalamus, and hypothalamus. The concentration of receptors is depicted by a pseudocolor scale ranging from blue (lowest), green, yellow, to red (highest) gradations. Fertility and Sterility 2009 92, 1-12DOI: (10.1016/j.fertnstert.2009.05.012) Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions

Figure 4 The opioid system and PCOS. Opioids increase the secretion of LH in response to GnRH. Opioids can also inhibit the clearance of insulin by the liver and stimulate production of insulin by the pancreas, both contributing to the hyperinsulinemia that can be observed in PCOS. Insulin and LH synergize to lead to excess androgen production by the ovaries. Insulin also inhibits production of sex hormone-binding globulin, leading to increased free androgens. Hyperandrogenism predisposes toward central adiposity and insulin resistance, as free fatty acids inhibit the uptake of glucose into muscle cells. Thus, the opioid system, hyperinsulinemia, and hyperandrogenism appear to be all involved in the metabolic and reproductive disturbances seen in PCOS. Fertility and Sterility 2009 92, 1-12DOI: (10.1016/j.fertnstert.2009.05.012) Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions